Global Orodispersible Film Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Orodispersible Film Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Orodispersible Film is an oral pharmaceutical dosage form that is generally in the form of a stamp-like flake. It will dissolve quickly after being put into the mouth and contact with saliva, and the dissolution time is usually tens of seconds. With more flexibility and comfort than tablets, capsules, solutions, Orodispersible Film can reduce drug swallowing problems in elderly and pediatric patients. Orodispersible Film is easy to manufacture and occupies an important position in the pharmaceutical industry with economical cost. It is mainly used in hospitals, clinics, pharmacies and other treatment places to improve patients' medication compliance in a painless form.

Market Overview:

The latest research study on the global Orodispersible Film market finds that the global Orodispersible Film market reached a value of USD 399.01 million in 2022. It’s expected that the market will achieve USD 644.62 million by 2028, exhibiting a CAGR of 8.32% during the forecast period.

Patients are more likely to absorb

Oral medicines are the most common and widely used in modern medicine due to their ease of use, accurate measurement, and ease of portability. Oral medicines account for about 60% of modern major medicines. However, commonly used oral drugs such as tablets, capsules, and pills may cause swallowing difficulties or even suffocation shock to some special patients. Orodispersible Film can solve such problems and improve patients' medication compliance and safety. Orodispersible Film dissolves in the mouth within minutes of contact with saliva, greatly enhancing the effectiveness of the API. Because it is directly absorbed into the systemic circulation through the mouth, it can eliminate the side effects of many oral drugs on the gastrointestinal tract. Combining Orodispersible Film with solid particles or nanoparticles can solve the problems of slow dissolution and low drug loading of some insoluble drugs. For children with poor compliance, Orodispersible Film with bright colors and good taste is more attractive. Compared with other forms of drugs, the development of low-dose children's Orodispersible Film has less changes in the ratio of raw materials, and the development is less difficult. Due to the aging and degeneration of organs, elderly patients often have difficulty swallowing during the use of traditional oral drugs. With the increasing level of medical care, the problem of global aging is becoming more and more serious, and the market size of medication for the elderly is also expanding. Elderly patients will become an important user group of Orodispersible Film. For special patients with poor compliance such as postoperative vomiting, long-term coma and patients with mental illness, they often cannot complete the swallowing process of oral administration and cannot cooperate with injections. Orodispersible Film provides patients with timely drug-assisted treatment due to its fast dissolution properties. For patients with chronic and sudden diseases, they need to hold drugs for a long time. The film packaging of Orodispersible Film can greatly reduce the storage space and inconvenience of taking medicine, and improve the convenience for patients to take medicine at any time. Some Orodispersible Films can work within seconds to achieve the purpose of sudden medication. Therefore, the easy solubility of Orodispersible Film can help patients take medicine more easily, which will become an important driving factor for the development of Orodispersible Film industry in the future.

Increased prevalence of neurological disorders

Orodispersible Film is suitable for therapies that require rapid drug absorption, such as the treatment of pain, allergies, sleep disorders and other symptoms, and is therefore widely used in the treatment of a series of neurological diseases such as schizophrenia and Alzheimer's disease. Economic growth is changing the lifestyles of people around the world, and obesity and high cholesterol levels increase the risk of stroke. The increasing trend of aging increases the prevalence of Parkinson's disease and Alzheimer's disease. According to 2021 figures from the Parkinson Foundation, more than 10 million people worldwide are living with Parkinson's disease. About 1 million people in the United States have Parkinson's disease. In the European Union, neurological diseases rank third after cardiovascular diseases and cancers. In Parkinson's disease, for example, patients often have symptoms such as tremors, slow movements, muscle stiffness, and speech changes, and death is caused by complications from late symptoms such as difficulty swallowing or falls. Therefore, people with Parkinson's disease are often more willing to take Orodispersible Film drugs because of concerns about choking. Medical professionals also prefer this dosage form because of the fast hydration and onset time of Orodispersible Film drugs. Hence, rising prevalence of neurological disorders is favorable for increasing the market size of Orodispersible Film.

limited drug load

Although compared to other oral drugs, Orodispersible Film has a larger surface area, which means faster wetting and dissolution. However, the limited size still limits the drug loading of Orodispersible Film to a relatively small range, generally 10 to 20 mg. Orodispersible Film companies cannot provide sufficient doses while maintaining fast dissolution properties and good taste, so they can only choose highly active drugs. While Orodispersible Film is great for children who need small doses and the flexibility to change doses, for adults who want to take an adequate dose of the drug, the number of single servings often needs to be increased. In contrast, injectable drugs are directly introduced into the subcutaneous or target site, and the drug can also be directly absorbed by the body, which also reduces the side effects of the drug on the gastrointestinal tract. Moreover, the injection drug has a high drug loading capacity and a small volume, which can prolong the drug action time. It is suitable for long-term treatment of chronic and senile diseases, and is conducive to improving patient compliance. Therefore, the limited drug loading of Orodispersible Film limits its market growth and is vulnerable to threats from other types of drugs.

Region Overview:

In 2021, the share of the Orodispersible Film market in North America stood at 38.21%.

Company Overview

IBSA, Kyukyu Pharmaceutical, Aquestive Therapeutics were the top 3 players in the Orodispersible Film market in 2022, taking up a market share of 31.80% together.

Segmentation Overview:

By type, Natural Polymer segment accounted for the largest share of market in 2021.

Application Overview:

By application, the Hospital and Clinic segment occupied the biggest share from 2017 to 2022.

Key Companies in the global Orodispersible Film market covered in Chapter 3:

Lubrizol Life Science
Aavishkar
Cure Pharmaceutical
CL Pharm
DK Livkon
Aquestive Therapeutics
Tapemark
Kyukyu Pharmaceutical
Umang Pharmaceuticals
Adhex Pharma
IBSA
Arx Pharma
ZIM Laboratories
Shilpa Therapeutics

In Chapter 4 and Chapter 14.2, on the basis of types, the Orodispersible Film market from 2018 to 2029 is primarily split into:

Natural Polymer
Synthetic Polymer

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Orodispersible Film market from 2018 to 2029 covers:

Hospital and Clinic
Drug Store
E-commerce

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)